Med Chemist

  • New diabetes drug may help people with obesity lose weight June 22, 2018
    In continuation of my update on semaglutideA compound that mimics a naturally occurring hormone that regulates appetite may help people who have obesity but not diabetes to lose weight, a new study suggests. The research will be presented Sunday, March 18, at ENDO 2018, the Endocrine Society's 100th annual meeting in Chicago, IllThe compound, semaglutid […]
    dr.umesh l
  • Drug used to treat daytime sleepiness does not appear to improve driving in those with sleep apnea June 21, 2018
     Armodafinil In "Does Armodafinil Improve Driving Task Performance and Weight Loss in Sleep Apnea? A Randomized Trial," Nathaniel Marshall, Ph.D., and his colleagues at the Woolcock Institute for Medical Research, University of Sydney, report on their study of armodafinil, which has been approved by the U.S. Food and Drug Administration to treat ex […]
    dr.umesh l
  • Novartis Drug Tasigna Approved by FDA to Treat Children with Rare Form of Leukemia June 20, 2018
    In continuation of my update on NilotinibNovartis announced today that the US Food and Drug Administration (FDA) expanded the indication for Tasigna (nilotinib) to include treatment of first- and second-line pediatric patients one year of age or older with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase (Ph+ CML-CP)In the Unite […]
    dr.umesh l
  • Oral drug reduces venous thromboembolism recurrence among cancer patients June 19, 2018
    In continuation of my update on  rivaroxabanResearch from the University of Warwick indicates that taking a tablet a day can help treat cancer patients of a potentially deadly condition.People with cancer have an increased risk of developing blood clots, with roughly one in five experiencing venous thromboembolism (VTE) - either deep vein thrombosis (DVT) or […]
    dr.umesh l
  • Osteoporosis drug may be cardioprotective in hip fracture patients June 18, 2018
    In continuation of my update on alendronateThe osteoporosis drug alendronate was linked with a reduced risk of cardiovascular death, heart attack, and stroke in a Journal of Bone and Mineral Research study of patients with hip fractures. The association was seen for up to 10 years after fracture.In the study, patients newly diagnosed with hip fracture from 2 […]
    dr.umesh l
  • New drug reduces symptoms of Rett syndrome in preclinical models June 15, 2018
    A new article published in the Cell Reports describes how a new drug is able to reduce the symptoms and activate the dormant neurons characteristic of Rett Syndrome in preclinical models. The study, led by Dr. Manel Esteller, Director of the Epigenetics and Cancer Biology Program (PEBC) of the Bellvitge Biomedical Research Institute (IDIBELL), ICREA Research […]
    dr.umesh l
  • FDA Approves Supplemental New Drug Application for Myrbetriq (mirabegron) for Use in Combination with Solifenacin Succinate for the Treatment of Overactive Bladder Symptoms June 12, 2018
    In continuation of my update on mirabegronAstellas Pharma Inc. announced  that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for the use of mirabegron in combination with the muscarinic antagonist solifenacin succinate for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinenc […]
    dr.umesh l
  • Mepivacaine is found to be an effective spinal anesthetic for knee replacement surgery June 11, 2018
    A numbing medicine largely abandoned decades ago for pain control during surgery could be making a comeback as an effective spinal anesthetic for today's modern-day knee replacement.In two companion studies by Henry Ford Health System, mepivacaine was found to be as effective for controlling pain with less side effects as bupivacaine, which for years ha […]
    dr.umesh l
  • FDA Approves Tafinlar + Mekinist for the Treatment of BRAF-Positive Anaplastic Thyroid Cancer June 8, 2018
    In continuation of my update on Tafinlar (dabrafenib) and Mekinist (trametinib)The U.S. Food and Drug Administration approved Tafinlar (dabrafenib) and Mekinist (trametinib), administered together, for the treatment of anaplastic thyroid cancer (ATC) that cannot be removed by surgery or has spread to other parts of the body (metastatic), and has a type of ab […]
    dr.umesh l
  • Methylene blue could hold the key to future anti-aging treatment June 7, 2018
    In continuation of my update on Methylene BlueIn a  keynote address to the 19th World Dermatology Congress, renowned dermatologist Dr. Saad Sami AlSogair noted that the past could hold the key to the future of anti-aging.Dr. AlSogair's presentation to a packed house, titled "Anti-Aging Potentials of Methylene Blue for Human Skin Longevity," pr […]
    dr.umesh l
  • Phase 2 study of dexpramipexole in hypereosinophilic syndromes meets its co-primary endpoints June 6, 2018
    Knopp Biosciences LLC today announced the publication of a report in the journal Bloodthat a Phase 2 study of dexpramipexole in hypereosinophilic syndromes (HES) met its co-primary endpoints.A team of investigators led by Dr. Amy Klion at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), under […]
    dr.umesh l
  • Study identifies molecule that may be critical to repair of white matter June 5, 2018
    In continuation of my update on hyaluronic acid (HA)A new study identifies a molecule that may be critical to the repair of white matter, the fatty tissue wrapped around parts of brain cells that helps speed up communication. Damage to white matter is associated with several conditions, including multiple sclerosis and cerebral palsy, and can occur in the br […]
    dr.umesh l
  • Osteoporosis drug prevents spread of basal-like breast cancer in mice June 5, 2018
    In continuation of my update on zoledronic acid Researchers in China have discovered that an enzyme called UGT8 drives the progression of basal-like breast cancer, an aggressive form of the disease that is largely untreatable. But the study, which will be published May 4 in the Journal of Experimental Medicine, reveals that the widely used osteoporosis drug […]
    dr.umesh l
  • Baldness treatment using a medication for osteoporosis June 1, 2018
    According to study leader Nathan Hawkshaw, of the University of Manchester in England, this new drug has never been considered in the treatment of baldness. It has been seen that the this could promote human hair growth. He said this could make a difference to people suffering from hair loss one day. To become a reality however, the drug would need to pass t […]
    dr.umesh l
  • ONC201 disrupts mitochondrial function and kills breast cancer cells, reveals study May 31, 2018
    TRAIL, a member of the TNF family of ligands, causes caspase-dependent apoptosis through activation of its receptors, death receptor 4 and DR5.ONC201 was originally identified as a small molecule that inhibits both Akt and ERK, resulting in dephosphorylation of Foxo3a and thereby induces TRAIL transcription.Recently, two independent groups, Wafik El Deiry at […]
    dr.umesh l
  • FDA grants approval for two drugs administered together to treat aggressive form of thyroid cancer May 30, 2018
     In continuation of my update on dabrafenib & trametinib     dabrafenib                 trametinibThe U.S. Food and Drug Administration approved Tafinlar (dabrafenib) and Mekinist (trametinib), administered together, for the treatment of anaplastic thyroid cancer (ATC) that cannot be removed by surgery or has spread to other parts of the body (metastatic […]
    dr.umesh l
  • New chemical trap catches trace glycoproteins, shows promise for targeted cancer treatments May 29, 2018
    Cancer drops sparse chemical hints of its presence early on, but unfortunately, many of them are in a class of biochemicals that could not be detected thoroughly, until now.Researchers at the Georgia Institute of Technology have engineered a chemical trap that exhaustively catches what are called glycoproteins, including minuscule traces that have previously […]
    dr.umesh l
  • Once-Daily Trelegy Ellipta Gains Expanded Indication in the US for the Treatment of Patients with COPD May 28, 2018
    In continuation of my update on fluticasone furoate, umeclidinium and vilanterolGlaxoSmithKline plc   and Innoviva, Inc.    announced that the US Food and Drug Administration,  has approved an expanded indication for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol ‘FF/UMEC/VI’), which means this medicine can now be used by US physicians to treat […]
    dr.umesh l
  • FDA Advisory Committee Votes in Favor of Lucemyra (lofexidine) for the Mitigation of Opioid Withdrawal Symptoms May 25, 2018
    US WorldMeds,  announced that the US Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee voted 11 to 1 to recommend approval of lofexidine for mitigating opioid withdrawal symptoms. If approved, lofexidine will be marketed under the brand name Lucemyra.The Advisory Committee's discussions were based on US WorldMeds' New […]
    dr.umesh l
  • Paratek’s New Drug Applications for Oral and Intravenous Omadacycline Accepted for Priority Review by FDA May 24, 2018
    Paratek Pharmaceuticals, Inc.   announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Applications (NDAs) and granted a priority review for omadacycline, an investigational once-daily oral and intravenous (IV) broad spectrum antibiotic. Paratek is seeking approval of omadacycline, a modernized tetracycline, for the treatment of […]
    dr.umesh l
  • Rubraca (rucaparib) Approved in the U.S. as Maintenance Treatment of Recurrent Ovarian Cancer May 23, 2018
    In continuation of my update on RucaparibClovis Oncology, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Rubraca (rucaparib) tablets for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemother […]
    dr.umesh l
  • Mylan Introduces Symfi (efavirenz, lamivudine and tenofovir disoproxil fumarate) Triple Combo Once-Daily HIV Treatment in the U.S. May 22, 2018
                 Tenofovir disoproxil fumarate                              Lamivudine                   Efavirenz           In continuation of my update, on Tenofovir, Lamivudine and EfavirenzGlobal pharmaceutical company Mylan N.V.  announced that it will introduce in the U.S. a third cost-saving HIV combination. The U.S. Food and Drug Administration (FDA) app […]
    dr.umesh l
  • Pacira Announces FDA Approval of Exparel as a Nerve Block to Produce Regional Analgesia May 21, 2018
    Pacira Pharmaceuticals, Inc., announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental new drug application (sNDA) to broaden the use of Exparel (bupivacaine liposome injectable suspension) to include administration via interscalene brachial plexus block to produce postsurgical regional analgesia. With this approval, Exparel i […]
    dr.umesh l
  • UCB Announces Briviact (brivaracetam) Now Approved by FDA to Treat Partial-Onset (Focal) Seizures in Pediatric Epilepsy Patients May 17, 2018
     In continuation of my update on brivaracetamUCB announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for the company’s newest anti-epileptic drug (AED) Briviact (brivaracetam) oral formulations indicated as monotherapy and adjunctive therapy in the treatment of partial onset (focal) seizure […]
    dr.umesh l
  • Novartis Receives FDA Approval of Tafinlar + Mekinist for Adjuvant Treatment of BRAF V600-Mutant Melanoma May 17, 2018
    Novartis announced that the US Food and Drug Administration (FDA) has approved Tafinlar® (dabrafenib) in combination with Mekinist® (trametinib) for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection. The FDA granted the combi […]
    dr.umesh l

Share

Leave a Reply

Your email address will not be published. Required fields are marked *


*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>